Equities

Acarix AB

Acarix AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.3335
  • Today's Change-0.002 / -0.45%
  • Shares traded4.99m
  • 1 Year change+39.67%
  • Beta1.6857
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.

  • Revenue in SEK (TTM)6.26m
  • Net income in SEK-70.95m
  • Incorporated2016
  • Employees9.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunovia AB (publ)885.00k-116.12m172.45m10.00--4.40--194.86-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Bactiquant A/S13.66m-22.02m178.64m----17.20--13.08-0.6558-0.65580.40640.29060.51012.945.06---82.23-41.26-92.65-47.16-24.3412.89-161.20-71.772.73-9.480.5326---0.689--7.62------
Neola Medical AB0.00-9.47m185.20m7.00--2.51-----0.1508-0.15080.001.050.00----0.00-12.63-17.04-13.59-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Arcoma AB175.30m12.66m196.46m31.0015.523.489.831.120.95980.959813.304.282.023.969.195,654,936.0014.611.1224.242.0137.8537.667.220.75681.2518.830.04070.0030.366.4134.81--22.75--
Nanexa AB26.91m-66.68m217.11m19.00--2.50--8.07-0.6938-0.69380.24840.64110.2108-3.832.991,416,316.00-52.24-40.77-70.59-48.77118.7777.27-247.79-532.261.92--0.0174--925.42147.00-30.44--39.10--
SpectraCure AB (publ)2.36m-21.18m222.43m13.00--1.89--94.09-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Scandinavian Medical Solutions A/S300.32m8.17m270.14m25.0032.902.3014.660.89950.19630.19637.222.811.381.8911.35--3.75--6.15--24.48--2.72--0.43075.540.3473--72.98--7.49------
Nexstim Oyj89.82m-9.45m285.46m39.00--13.48--3.18-0.1223-0.12231.190.27610.81960.22235.28214,040.30-8.62-26.77-14.02-43.9097.2492.11-10.52-38.381.24-5.510.7716---23.9422.08-201.58--19.51--
Micropos Medical AB (publ)2.68m-22.68m305.25m9.00--14.92--113.86-0.2463-0.24630.0220.13410.09940.13151.20335,122.50-84.10-64.24-111.33-82.2779.96114.76-845.91-767.573.18--0.0184--50.235.94-26.57------
INIFY Laboratories AB3.44m-51.69m306.07m23.00--4.16--88.99-1.18-1.180.07851.680.0322.990.6608---48.10---48.10--76.42---1,503.10------0.00--------------
Ortoma AB43.22m-30.78m322.32m7.00--1.95--7.46-0.8112-0.81121.244.670.22941.014.496,173,962.00-16.34-10.45-17.53-11.6486.83339.86-71.22-175.523.04--0.00-------38.87--14.14--
Acarix AB6.26m-70.95m326.01m9.00--4.81--52.10-0.1168-0.11680.00950.06970.08940.11722.47---101.38-66.93-123.43-77.1288.2779.42-1,133.87-1,483.685.21-328.980.00--7.2043.55-1.11------
Karolinska Development AB1.90m-5.65m337.08m8.00--0.2762--177.13-0.0209-0.02090.0074.560.0015--1.38237,875.00-0.45363.37-0.45783.83-----296.851,466.36----0.00210.00-12.43-8.10106.11-29.31----
Boule Diagnostics AB572.53m21.28m338.62m230.0016.240.68247.140.59150.53680.536814.4512.780.7244.193.692,511,092.002.681.673.712.4043.8643.503.702.040.92684.720.269842.244.246.1396.24-9.45-9.74--
Q linea AB4.70m-224.61m362.04m99.00--5.32--77.11-2.06-2.060.04280.58130.02770.170711.8636,968.50-132.70-59.66-356.93-66.14-56.25-378.58-4,783.96-4,046.970.6999--0.4555---65.2833.0214.64--41.94--
ContextVision AB133.06m25.82m430.74m41.0016.684.7712.453.240.34450.34451.781.211.212.334.813,433,738.0023.3929.3930.6743.2797.3998.5819.4027.153.99--0.0304--12.197.78-1.77---35.88--
Data as of Sep 19 2024. Currency figures normalised to Acarix AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 30 Aug 2024162.18k0.02%
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.